The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Gsk share price .a slow death
When are the 'next results' by the Dame?
I am sure their shall be positive spin!!!
Gsk share price.death by 1.000 cuts
Who from ?
I reckon we are almost certain to get a bid -albeit not a very attractive one- but it just might go contested. I am hanging on.
GSK PE Ratio: 4.122 for June 1, 2023
Really positive but thi only responds by going DOWN - as usual.
AZN trading at >20x
GSK has a solid pipeline and oncology plays
Not a long term one to hold for growth but divi not too bad. I keep a few sentimental Wellcome plc shares (WF plc -> GW -> GSK). These shares hit around £20+ about 20 years ago just as I retired. So quite a lot of downward growth! BTW around the 90s both GW & AZN were approx both around £7 ce la vie.
...f could buy at this great low price instead of being a long term holder with other priorities in my p/f. For those readers who don't have this heavyweight creator of needed and exciting new drugs in their p/f, this is a great low price to satart adding. Please do a bit of homework and you could well agree/
Don't rule out foreign stakebuilding at this level.
....advises buy and hold underalued GSK, just as I did on a recent post. Stacks of value in their new drugs. If they don't move up soon, my view is still they will get takeover bids.
Price dipped some ,Also good to see more purchases showing . For the point of it ,might be interesting to look at bsfa share price today and in 3 and 6 months with the news expected .Want to see gsk price moving up more .
Https://www.gsk.com/en-gb/investors/dividend-and-share-price/dividend-calendar/
Is it ex dividend date today which would explain why it has dropped ?
Haven’t seen any news for this recent drop and every one else seems on the up!
As a retired litigation lawyer I am really comforted by the continued failure of litigants here against GSK.
Most if not all of these litigants will have been taken on 'no win no fee' and with a number of class actions now dismissed,
legal firms must be getting the wind up. Especially comforting was the last dismissal because it was by a Judge in Canada, not USA,
The sp does not reflect the way this cookie is crumbling. Without the Zantac litigation and with the number and extent of new FDA successes, my opinion is that GSK is far too cheap and at present a prime candidate for a takeover fight at £20 or more.
Paul Offit [ex FDA vaccines advisory committee member] gives his thoughts on GSK's RSV vaccine
https://pauloffit.substack.com/p/a-new-life-saving-vaccine-for-older
Good news & bad news from the article:
'The new RSV vaccine is a welcome addition in the fight against RSV. Now that it has been licensed by the FDA, it is likely that the CDC will recommend it for all adults over 60 at a meeting in June. Also, a similar RSV vaccine for older adults made by Pfizer will likely be considered by the FDA for licensure within a few weeks.'
But this is a big pie, so even if it is shared with Pfizerit could add tens of percent onto the annual free cash flow. First mover advantage could play into GSKs favour.
Sale of £804m worth of Haleon stock.
A positive court ruling from Canada relating to ranitidine.
Positive results in a phase III trial of its 5-in-1 meningococcal ABCWY vaccine candidate.
A very good day 😃
.
SaMason56 - Market is shot at present. This is now a posssible bid stock first and foremost but who knows when.
I am completely and utterly at a loss as to how GSK can gain approval for a first to market vaccine and it not have any impact on the share price. In fact since the news broke globally the share price has gone down.
This is huge news and a massive success…….No?
I give up
Another winner for us and now approved in the US too.
We need to make hay whilst we have the only fully approved vaccine for RSV.
https://www.cnbc.com/2023/05/03/rsv-vaccine-fda-approves-gsk-shot-for-older-adults.html?__source=androidappshare
...the weak pound since many of its sales will be for dollars and other currencies. Very undervalued.